Transforming the treatment of pain and inflammation with breakthrough science

Our science leverages two crucial insights by Dr. John L. Wallace and his colleagues. The first identified the mechanism by which NSAIDs cause stomach ulcers and bleeding—radically altering the prevailing medical doctrine. A decade later, his discovery of hydrogen sulfide’s anti-inflammatory potential led to the research project that evolved into Antibe Therapeutics.

John L. Wallace
Founder & Chief Scientific Officer

Today’s solutions FOR ACUTE pain

The main mechanism of NSAID-induced gastrointestinal damage was identified in 1990 by Dr. John L. Wallace and his colleagues. Several scientific and commercial attempts have since been made to overcome the problem. These have included the development of selectively targeted NSAIDs, the use of enteric coatings, and co-administration of stomach acid reduction medications. None of these efforts have solved the gastrointestinal toxicity of NSAIDs, and some have resulted in increased risk to the digestive tract and other body systems.

Hydrogen Sulfide and cellular function

In 2002, hydrogen sulfide was identified as one of three biologically important gases, now collectively termed gasotransmitters or gaseous mediators.  Previously viewed as hostile to life, hydrogen sulfide—along with nitric oxide and carbon monoxide—have emerged as central to biology, important in a wide range of cellular functions. In 2003, Dr. Wallace and his colleagues began investigating hydrogen sulfide’s anti-inflammatory properties. Over the succeeding years, their work would demonstrate its GI-sparing potential, leading to the design of Antibe’s hydrogen sulfide platform.

Science Timeline

* Dr. Ignarro is co-chair of Antibe′s Scientific Advisory Board.
** NicOx is the first company to develop and gain regulatory approval for gasotransmitter-based therapeutics.

Science Timeline

*  Dr. Ignarro is co-chair of Antibe′s Scientific Advisory Board.
** NicOx is the first company to develop and gain regulatory approval for gasotransmitter-based therapeutics.

Attention

This is an external link. Click “OK” to continue.

CANCEL OK